In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.
The Ins & Outs of ILD: The Management & Treatment of ILD in Patients with Rheumatic Disease
Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.
How to Manage Critical Illness in Patients with Autoimmune Disease
Patients in intensive care may experience dangerous manifestations of rheumatic disease, such as digital ischemia, multi-system organ failure and more. In a session at ACR Convergence 2021, experts addressed how to manage and treat these critically ill patients.
Longitudinal Knowledge Assessment Offers New Approach to Board Certification
The American Board of Internal Medicine’s recently launched Longitudinal Knowledge Assessment for rheumatology maintenance of certification emphasizes convenience and ongoing learning.
ACR Town Hall Provides Update on Oral Antiviral Therapy for COVID-19
At an ACR COVID-19 town hall on COVID-19, infectious disease experts discussed the most up-to-datecurrent information on pre- and post-exposure monoclonal antibody therapy, oral antivirals and vaccines for rheumatology patients.
Partnership Amplifies Advocacy Reach
Working with the AMA provides a megaphone to amplify rheumatology’s voice at both federal and state levels. This year is the AMA’s next five-year membership review. Join the AMA or renew your membership now to keep the ACR represented in AMA policy bodies.
Key 2022 Coding & Billing Updates
In 2022, rheumatology practices should prepare for documentation, coding, billing and reimbursement revisions related to evaluation and management (E/M), split/shared billing policies and telehealth services.
Risankizumab Effective Against Refractory Psoriatic Arthritis
NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…
Lab Study Suggests Zinc May Worsen Rheumatoid Arthritis
NEW YORK (Reuters Health)—Zinc supplementation may exacerbate rheumatoid arthritis (RA), new laboratory data suggest. In monocytes from patients with RA, researchers found high concentrations of intracellular zinc, which regulates immune responses by affecting signaling pathways, according to a report in Science Signaling.1 They also found increased expression of Zip8, a zinc-specific importer, in peripheral and…
ACR Insurance Subcommittee Chair Encourages Member Engagement
Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 805
- Next Page »